People hoping to lose a few pounds by substituting artificial sweeteners for regular sugar may end up disappointed, suggests a fresh look at past research.
Abbott and Bigfoot Biomedical announced that the companies entered into an agreement to develop and commercialize diabetes management systems, integrating Abbott’s FreeStyle Libre glucose sensing technology with Bigfoot’s insulin delivery solutions in the United States.
Novo Nordisk and Glooko announced that the new Cornerstones4Care Powered by Glooko app (C4C app) is now available to help people more effectively manage their diabetes.
Roche bought Vienna-based diabetes management platform mySugr, joining a crowd of companies expanding app-based digital health services.
Medtronic Plc said it signed an agreement with health insurer Aetna Inc. under which payment for its insulin pump systems will be tied to how well diabetes patients fare after switching from multiple daily insulin injections.
Google is betting on the potential of European biotech companies to deliver life-changing drugs by investing alongside Swiss company Novartis in a new $300 million fund run by leading life sciences investment firm Medicxi.
Analysis of international study shows broad benefits regardless of pre-existing cardiovascular disease or which class of SGLT2 inhibitor SAN DIEGO, June 13, 2017 /PRNewswire-USNewswire/ — A new class of medication, known as sodium-glucose transporter-2 (SGLT2) inhibitors, is associated with lower rates of death and hospitalization for heart failure when used to treat patients […]
Johnson & Johnson’s type 2 diabetes drug Invokana significantly reduced the risk of serious heart problems in patients with established heart disease or at elevated risk in a pair of large studies, according to data presented at a medical meeting.
France’s Sanofi and partner Regeneron Pharmaceuticals said their anti-cholesterol drug Praluent recorded positive results in its first dedicated studies involving patients with diabetes and high cholesterol.
Merck in partnership with Pfizer Inc. announced that two Phase 3 studies of ertugliflozin met their primary endpoints.